Yttrium (90Y) tacatuzumab tetraxetan

Yttrium (90Y) Tacatuzumab Tetraxetan: An Advanced Cancer Therapeutic Agent[edit]

Yttrium (90Y) tacatuzumab tetraxetan, commercially known as AFP-Cide, represents a pioneering advancement in the realm of cancer therapeutics. It is a monoclonal antibody that has been humanized and subsequently conjugated to a chelator to enable the binding of a potent radioisotope, aimed at targeting and eradicating tumor cells.

Mechanism of Action[edit]

The primary component of this drug, tacatuzumab, is a humanized monoclonal antibody. Monoclonal antibodies are proteins designed to recognize and bind to specific targets on the surface of cancer cells^[1].

For enhanced therapeutic efficacy, tacatuzumab is conjugated with tetraxetan, a chelating agent. This chelator facilitates the binding of the yttrium-90 radioisotope to the antibody^[2]. Yttrium-90, being a beta-emitting isotope, releases radiation that can destroy tumor cells, thus offering targeted radiation therapy^[3].

Applications in Oncology[edit]

The conjugation of the tacatuzumab antibody with yttrium-90 leverages the specificity of the antibody to direct the cytotoxic effects of radiation to the tumor, sparing most of the surrounding healthy tissues. This targeted approach potentially offers:

Reduced side effects compared to non-targeted radiation therapies.
Enhanced tumor cell eradication due to the direct delivery of the radioactive agent.

While Yttrium (90Y) tacatuzumab tetraxetan is primarily intended for cancer treatment, the specific types of cancers it best addresses and the stages at which it is most effective would need further clinical validation.

Current Status and Development[edit]

As with many experimental therapeutics, Yttrium (90Y) tacatuzumab tetraxetan is undergoing rigorous evaluation in both preclinical studies and clinical trials to ascertain its safety, efficacy, and optimal administration regimen.

It's crucial to note that while the promise of such therapies is high, their transition from the laboratory to clinical practice requires extensive research and iterative refinement to ensure both safety and therapeutic efficacy^[4].

Conclusion[edit]

The development of Yttrium (90Y) tacatuzumab tetraxetan epitomizes the advancements in precision oncology, where targeted therapies are poised to revolutionize cancer treatment. As research progresses, this drug may offer a beacon of hope for patients battling certain types of cancers.

References[edit]

↑ Reichert, J. M. (2016). Antibodies to watch in 2016. MAbs, 8(2), 197-204.
↑ Scheinberg, D. A., & Villa, C. H. (2019). Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews Clinical Oncology, 16(5), 312-325.
↑ Wright, C. L., & Werner, T. J. (2019). Therapeutic applications of yttrium-90 radioembolization. Future Oncology, 15(6), 637-652.
↑ Kontermann, R. E. (2017). Strategies for extended serum half-life of protein therapeutics. Current opinion in biotechnology, 48, 152-159.

This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page.

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

Structure of Y-90 tacatuzumab tetraxetan

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Reichert, J. M. (2016). Antibodies to watch in 2016. MAbs, 8(2), 197-204.

[2] Scheinberg, D. A., & Villa, C. H. (2019). Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews Clinical Oncology, 16(5), 312-325.

[3] Wright, C. L., & Werner, T. J. (2019). Therapeutic applications of yttrium-90 radioembolization. Future Oncology, 15(6), 637-652.

[4] Kontermann, R. E. (2017). Strategies for extended serum half-life of protein therapeutics. Current opinion in biotechnology, 48, 152-159.

[1]

[2]

[3]

[4]